Inhibitory Effect of Allyl Isothiocyanate on Platelet Aggregation

Subscriber access provided by Otterbein University

Article

Inhibitory Effect of Allyl Isothiocyanate on Platelet Aggregation Do-Seop Lee, Tae-Ho Kim, and Yi-Sook Jung J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/jf4041518 • Publication Date (Web): 01 Jul 2014 Downloaded from http://pubs.acs.org on July 1, 2014

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 32

Journal of Agricultural and Food Chemistry

Inhibitory Effect of Allyl Isothiocyanate on Platelet Aggregation

Do-Seop Lee†, Tae-Ho Kim†, Yi-Sook Jung*, †, ‡ †

College of Pharmacy, Ajou University, Suwon 443-749, Republic of Korea

‡

College of Pharmacy, Research Institute of Pharmaceutical Sciences and Technology, Ajou

University, Suwon 443-749, Republic of Korea.

AUTHOR INFORMATION * Coressponding author Yi-Sook Jung, Ph.D. College of Pharmacy, Ajou University San 5, Woncheon-dong, Youngtong-gu, Suwon 443-749, Republic of Korea Telephone: +82-31-219-3444 Fax: +82-31-219-3435 E-mail: [email protected]

ACS Paragon Plus Environment

1


Page 2 of 32

1

ABSTRACT

2

Allyl isothiocyanate (AITC) is one of the major components of mustard. The present study

3

for the first time attempted to evaluate the effect of AITC on platelet aggregation. In the in vitro

4

study using platelet rich plasm (PRP) from rat and human, AITC at the concentrations of 100 and

5

300 µM significantly inhibited platelet aggregation induced by collagen, thrombin, ADP, and

6

arachidonic acid. AITC also attenuated thromboxane A2 production and ATP release in rat and

7

human PRP. AITC elicited inhibitory effects on cellular Ca2+ increase and platelet shape change

8

in rat PRP. AITC further showed inhibitory effects on the phosphorylation of PKCδ, p38, ERK,

9

and Akt in rat PRP. In the rat ex vivo study, 1 and 3 mg/kg (p.o.) of AITC showed significantly

10

inhibitory effect on platelet aggregation. Furthermore, AITC showed protective effect in

11

thromboembolism attack model in mouse. These results suggest that AITC has remarkable anti-

12

platelet effects and maybe a therapeutic potential for the prevention of aberrant platelet

13

activation-related disorders.

14 15 16

Keywords

17

Allyl isothiocyanate, Platelet, Aggregation, Thromboxane A2, ATP

18 19 20 21 22


2

Page 3 of 32


23

INTRODUCTION

24

Platelets play an essential physiological role in hemostasis by permitting the formation of

25

blood clots. However, the aberrant activation of platelets by pathological factors and subsequent

26

thrombogenesis are commonly associated with atherosclerotic lesions. Indeed, thrombosis and

27

embolization contribute to cardiovascular diseases such as ischemic heart disease and stroke.1

28

Therefore, a suitable anti-platelet therapy is critical for preventing the progression of

29

cardiovascular diseases.2 A number of anti-platelet drugs, including clopidogrel, have been

30

developed and are used clinically to prevent thrombosis. However, some of the chemically

31

synthesized anti-platelet agents may be related to adverse effects, such as gastrointestinal

32

bleeding, and palpitation. Considering that plant constituents have a nature-friendly image and

33

various safety merits, much effort recently has been devoted toward developing herbal medicines

34

for the prevention of thrombosis and atherosclerotic diseases. 3, 4

35

Mustard (Brassica spp.), one of the first domesticated crops, is a widely consumed vegetable

36

5

37

East Asia use mustard oil as the cooking oil. Mustard and mustard oil have been reported to have

38

physiological effects such as anti-inflammation6 and anti-tumor7. Recently, it has been reported

39

that polyunsaturated fatty acid-rich mustard oil has anti-platelet effect in ex vivo study.8 However,

40

there is little information about anti-platelet effect of mustard oil in in vitro study. In addition, its

41

active constituent and inhibitory mechanism is still unknown. Allyl isothiocyanate (3-

42

isothiocyanato-1-propene, AITC) is the chief constituent of mustard oil9, 10 and causes pungent

43

flavor. AITC has been used as a food additive for its flavor-enhancing, antibacterial, anti-fungal

44

effects.11 In addition, studies using animal models have shown that AITC inhibits bladder cancer

and currently grown on millions acres in the North America and India. Also, many people of


3


Page 4 of 32

45

growth, attenuates levels of inflammatory markers such as interleukin-1β, and reduces blood

46

glucose levels.12-14 However, the anti-platelet effects of AITC have not been evaluated.

47

This study for the first time evaluated the effects of AITC on platelet aggregation and its

48

mechanism of action, focusing on Thromboxane A2 (TXA2) production and ATP release in

49

platelet from rat and human blood. In addition, its ex vivo anti-platelet effect in rat and its in vivo

50

protective effect from thromboembolism attack in mouse were also investigated.

51 52

MATERIALS AND METHODS

53

Reagents. Allyl isothiocyanate (AITC) at 95% purity, apyrase, acetylsalicylic acid (ASA),

54

bovine serum albumin (BSA), fura 2-AM, polyethylene glycol (PEG), β-nicotinamide adenine

55

dinucleotide (reduced form, β-NADH), U46619 and pyruvic acid were obtained from Sigma

56

Chemical Co. (St. Louis, MO, USA). Collagen, thrombin, adenosine diphosphate (ADP), and

57

arachidonic acid (AA), and luciferin-luciferase reagent were purchased from Chrono-Log Co.

58

(Harvertown, PA, USA). Thromboxane B2 EIA kits were purchased from Cayman Chemical Co.

59

(Ann Arbor, MI, USA). Antibodies against PLCγ, phosphor-PLCγ, PKCδ, phospho-PKCδ, ERK,

60

phospho-ERK, p38, phospho-p38, Akt, and phospho-Akt were purchased from Cell Signaling

61

(Danvers, MA, USA).

62

Animals. Animals were purchased from Samtako Laboratory Animal Center (Suwon,

63

Korea). Spargue-Dawley (SD) rats (8 weeks, 220-240 g) and ICR mouse (8 weeks, 34-40 g)

64

were used for experiments. They were housed in a conventional animal facility with free access

65

to food and water in a temperature- and relative humidity-controlled environment under a 12-

66

/12-h lighting schedule. The animals were acclimatized at least 7 days before experiments.

67

Animal study protocols conformed to the guidelines in the Guide for the Care and Use of


4

Page 5 of 32


68

Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-

69

23, revised 1996), and were approved by the Committee on Animal Research at Ajou Medical

70

Center, Ajou University

71

Experimental treatment. For in vitro experiments, AITC and ASA were dissolved in 70%

72

PEG-saline. The final concentration of 70% PEG-saline never exceeded 0.1%. For ex vivo and in

73

vivo experiments, AITC and ASA were dissolved in 70% PEG-saline. 70% PEG-saline solution

74

did not influence platelet aggregation. All agents were prepared just before use.

75

Preparation of platelet rich plasma (PRP) from rat and human blood. PRP from rat

76

blood was prepared as described previously.15, 16 Briefly, Sprague-Dawley (SD) rats weighing

77

200–240 g were lightly anesthetized with diethyl ether. A volume of 8–10 ml of blood was

78

collected from the abdominal aorta into a syringe containing 3.8% sodium citrate. The ratio of

79

blood to 3.8% sodium citrate was adjusted to 1:9 v/v. After centrifugation at 150 g for 10 min at

80

room temperature, supernatants (PRP) were used for the aggregation study. To prepare washed

81

platelets (WP), blood was collected into a syringe containing acid citrate dextrose (ACD: 2.5%

82

trisodium citrate, 2% dextrose, and 1.5% citric acid) and adjusted to a ratio of 1:9 v/v. After

83

centrifugation at 150 g for 10 min at room temperature, the platelets were isolated and then

84

centrifuged again at 150 g for 10 min in washing buffer (Tyrode’s solution containing 10% ACD

85

buffer and 0.3% BSA). Platelets were diluted with Tyrode’s solution (NaCl 11.9 mM, KCl 2.7

86

mM, MgCl2 2.1 mM, NaH2PO4 0.4 mM, NaHCO3 11.9 mM, glucose 11.1 mM, and bovine

87

serum albumin 3.5 mg/ml, pH 7.2). To make platelet-poor plasma (PPP) from rat blood, PRP

88

were centrifuged at 1200 g for 10 min at room temperature and supernatants were obtained as

89

PPP. For PRP from human blood, the human platelet suspensions were supplied from Red Cross


5


Page 6 of 32

90

(Suwon, Korea). The human blood was collected from healthy human volunteers who had not

91

taken medicine indicated by Red Cross guide.

92

In vitro platelet aggregation and shape change in rat PRP. The platelet aggregation study

93

was performed as previously described.17, 18 Briefly, PRP was diluted with Tyrode’s solution

94

containing 0.3% BSA and adjusted to about 2 × 108 platelets/ml. PRP was stimulated to

95

aggregate by using different aggregating agents at the following final concentrations: collagen, 2

96

µg/ml; thrombin, 0.2 U/ml; ADP, 2.5 µM; AA, 100 µM and U46619 1 µM. We decided the

97

concentrations of agonists based on the results from preliminary experiments (data not shown).

98

Platelet aggregation was recorded for 5 min after stimulation by using whole blood/optical Lumi-

99

Aggregometer (chrono-log, Havertown, PA). Aggregations were measured and expressed as percent

100

changes in light transmission with respect to PPP. Data of light transmission assay was calculated to

101

percent change by using chronolog-software. In the in vitro study, PRP was pre-incubated with

102

AITC or ASA at 37°C for 3 min before being stimulated with the aggregating agents. To monitor

103

shape change, platelet shape change study was performed as previously described.19 Platelets (2

104

× 108 platelets/ml) were pre-incubated with apyrase (2 U/ml), indomethacin (10 µM) and EGTA

105

(1 mM), before addition of collagen.

106

Determination of cytotoxicity in rat PRP. To determine the cytotoxicity of AITC, lactate

107

dehydrogenase (LDH) release from platelets was measured as previously described.20 After

108

incubating PRP (2 × 108 platelets/ml) with 70% PEG-saline or different concentrations of AITC

109

for 3 min at 37°C, PRP was centrifuged at room temperature at 10,000 × g for 1 min. A 25-µl

110

aliquot of the supernatant was mixed with 100 µl of NADH solution (0.03% β-NAD, reduced

111

form of the disodium salt in phosphate buffer) and 25 µl of pyruvate solution (22.7 mM pyruvic

112

acid in phosphate buffer) at room temperature. Reductions in absorbance at 340 nm because of

113

conversion of NADH to NAD+ were measured to determine LDH activity in supernatants. LDH


6

Page 7 of 32


114

release is expressed as the percentage of the total enzyme activity in platelets completely lysed

115

with 0.2% triton X-100.

116

Measurement of TXA2 production and ATP release in rat and human PRP.

117

Measurement of TXA2 production was conducted using a TXB2 EIA kit (Cayman Chemical Co,

118

Ann Arbor, MI, USA) as previously described.21 PRP (2 × 108 platelets/ml) was incubated for 3

119

min in the presence or absence of samples, and then collagen (2 µg/ml) was added and PRP was

120

incubated at 37°C for 5 min with stirring. EDTA (10 mM) was added to stop TXA2 production.

121

After centrifugation at 12,000 g for 3 min, the amount of TXB2 was measured according to the

122

manufacturer’s instructions.

123

Detection of ATP release was determined as previously described.22 PRP (2 × 108

124

platelets/ml) was incubated at 37°C with stirring at 1,200 rpm. After addition of the luciferin-

125

luciferase reagent, collagen (2 µg/ml) was added to initiate the reaction. PRP was incubated with

126

AITC (30, 100, 300 µM) for 3 min before the addition of luciferin-luciferase reagent.

127

Determining the [Ca2+]i in rat PRP. The intracellular Ca2+ was determined with fura-2/AM

128

as described previously.23 Briefly, the PRP was incubated with 6µM of fura-2/AM for 60 min at

129

37℃. The fura-2-loaded washed platelets (108 ml-1) were then pre-incubated with AITC for 3

130

min with 1 mM CaCl2. Next, WPs were stimulated with collagen 2 µg/ml for 5 min. Fura-2

131

fluorescence was measured in a spectrofluorometer with an excitation wavelength that ranges

132

from 340 to 380 nm, changing every 0.5s, and emission wavelength of 510 nm. The [Ca2+]i was

133

calculated.24

134

[Ca2+]i in cytosol = 224 nM x (F – Fmin) / (Fmax – F)

135

224 nM: dissociation constant of the fura-2-Ca2+ complex and Fmin and Fmax represent the

136

fluorescence intensity levels at very low and very high Ca2+ concentrations respectively. Fmin is


7


Page 8 of 32

137

the fluorescence intensity of the Fura-2-Ca2+ complex at 510 nm, after the platelet suspension

138

containing 20 mM Tris/10 mM of EGTA had been solubilized by 0.1% Triton X-100. Fmax is the

139

fluorescence intensity of the Fura-2-Ca2+ complex at 510 nm, after the platelet suspension

140

containing 1 mM CaCl2 had been solubilized by 0.1% Triton X-100. F indicates the fluorescence

141

intensity of the fura-2-complex at 510 nm after WPs were stimulated by collagen, with 1mM

142

CaCl2 and AITC or vehicle.

143

Western blotting. The immunoassay was performed as previously described.4 The WPs (2

144

× 108 platelets/ml) were stimulated by collagen (2 µg/ml) in the presence or absence of AITC

145

(300 µM). Reactions were terminated by adding 10 mM EDTA and centrifuged at 12,000 g for 3

146

min. After adding ice-cold platelet lysis buffer (1% NP40, 15 mM HEPES, 75 mM NaCl, 1 mM

147

EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium fluoride (NAF), 1 mM

148

Na3VO4, 1 µg/ml leupeptin, and 1 µg/ml aprotinin; pH 7.4), lysates were centrifuged at 13,000 g

149

for 10 min at 4°C. The supernatants were collected and protein concentration was determined

150

using a BCA protein assay (Thermo Scientific, IL, USA). Equal volumes of protein were

151

resolved using SDS-PAGE (10%) and transferred to PVDF membranes. The PVDF membranes

152

were blocked with 5% nonfat dry milk in TBS and incubated with the primary antibody diluted

153

in TBS buffer (1:1000 ratio, 4°C overnight). Immunoblots were then incubated again with a

154

horse radish peroxidase (HRP)-conjugated secondary antibody and then the immune-reactive

155

bands were visualized with a LAS 4000 (Fuji, Honshu, Japan) using a western blot detection

156

system (WestZol, Intron, Seoul, Korea).

157

Ex vivo platelet aggregation study in rat. Two hours before experiments, SD rats were

158

orally administered 70% PEG-saline, AITC (0.3, 1, 3 mg/kg), or ASA (50 mg/kg). Rat blood

159

samples were collected and the platelet aggregation study was performed as described above.


8

Page 9 of 32


160

In vivo acute pulmonary thromboembolism study in mouse. Acute pulmonary

161

thromboembolism model was performed as previously described.25 Male ICR mouse weighing

162

35-40 g were fasted for 6 hour before experiments. AITC and ASA were dissolved in 70% PEG-

163

saline. Mice were orally administered AITC or ASA before 2 hours performed experiments.

164

Collagen 500 µg/kg plus epinephrine 25 µg/ml was injected to the tail vein to induce thrombosis.

165

Each mouse watched for 15 min whether the mouse was paralyzed, dead or recovered from acute

166

thrombotic challenge.

167

In vivo mouse tail bleeding time assay. Mouse tail bleeding times were recorded as

168

previously described.26,

27

169

experiments. Two hours after the oral administration of AITC (0.3, 1, 3 mg/kg) or ASA (50

170

mg/kg), the mice were anesthetized with ketamine 100 mg/kg and xylazine 10 mg/kg. Thereafter,

171

the mice were individually placed on a hotplate to control body temperature and tails were

172

transected 3 mm from the tips by using a razor blade. The tail was then immersed in a 15-ml

173

clear conical tube containing warmed saline (37°C). The time until the cessation of blood flow

174

was then measured. Bleeding time was defined as the time taken for bleeding stopped for 15 s.

Male ICR mice weighing 35–40 g were fasted for 16 h before

175

Statistical analysis. In thromboembolism experiment, the chi-square test was used to

176

determine significant differences between the vehicle and treated groups. Statistical significance

177

was considered at P

Inhibitory Effect of Allyl Isothiocyanate on Platelet Aggregation

Recommend Documents